Successful low‐dose immunotherapy after kidney transplantation in a 10‐year‐old girl with Schimke immuno‐osseous dysplasia

Abstract

AbstractBackgroundThis case report highlights a successful steroid‐free, low‐dose immunosuppressive protocol for renal transplantation in a pediatric patient with Schimke immuno‐osseous dysplasia with excellent 7‐year patient and graft survival. Schimke immuno‐osseous dysplasia is a rare multisystem disorder involving the kidney. Renal transplantation is a therapeutic option, but posttransplant mortality is high due to severe infections and posttransplant lymphoproliferative disease.MethodsA 10‐year‐old girl diagnosed with Schimke immuno‐osseous dysplasia and end‐stage renal disease underwent an AB0‐compatible living‐related kidney transplantation, with no donor‐specific antibodies. Our standard immunosuppression protocol was modified due to the risk of infection. Basiliximab was used as induction therapy, and a reduced dose of mycophenolate mofetil and tacrolimus was initiated following transplantation, maintaining the patient on a low tacrolimus target (3–5 μg/L). Mycophenolate mofetil was discontinued after 8 weeks due to neutropenia and the patient was kept on tacrolimus as monotherapy. Five years posttransplant the patient developed acute onset of neurological symptoms, consisting of ataxia, lack of voluntary coordination, balance, aphasia and dysphagia, and diplopia. She recovered without neurological deficits within 6 weeks. Extensive evaluation revealed no pathology. To avoid a possible a component of tacrolimus‐induced cerebral vasoconstriction, the immunosuppressive therapy was changed to everolimus.ResultsSeven years posttransplant, the patient has experienced no serious infections, no rejections, and had excellent graft function, and no de novo donor‐specific antibodies.ConclusionsThe present results indicate that low‐dose immunosuppressive therapy after renal transplantation with low immunological risk should be considered for patients with Schimke immuno‐osseous dysplasia.